Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.46 |
| ▸ | TDO2 | P48775 | 5/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR5A | P47898 | 2/20 | 0.40 |
| ▸ | MPL | P40238 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | GABRE | P78334 | 2/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2044016 | 0.77 | KIF11 (0.46) | KIF11TDO2HTR2BHTR5AGABRP | |
| SCHEMBL4901535 | 0.74 | KIF11 (0.42) | KIF11TDO2HTR2BHTR5AMPL | |
| SCHEMBL25231690 | 0.74 | KIF11 (0.59) | KIF11TDO2HTR2BHTR5AMPL | |
| SCHEMBL18691283 | 0.71 | KIF11 (0.51) | KIF11TDO2HTR2BHTR5AMPL | |
| SCHEMBL13563976 | 0.70 | KIF11 (0.78) | KIF11TDO2HTR2BHTR5AMPL | |
| SCHEMBL29178250 | 0.69 | KIF11 (0.56) | KIF11TDO2HTR2BHTR5AMPL | |
| SCHEMBL458963 | 0.68 | KIF11 (0.55) | KIF11TDO2HTR2BHTR5AGABRP | |
| SCHEMBL29832015 | 0.68 | KIF11 (0.55) | KIF11TDO2HTR2BHTR5AGABRP | |
| SCHEMBL15430845 | 0.68 | KIF11 (0.46) | KIF11TDO2HTR2BHTR5AGABRP | |
| SCHEMBL4137851 | 0.68 | AHR (0.53) | KIF11GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4074658-B2 | — | — | 2008-04-09 | — | — | JP | claimed |
| EP-0636028-B1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM COMPRISING AN AMPHIPHATIC CATIONIC PEPTIDE | UNIV CALIFORNIA (US) | 2004-03-03 | — | — | EP | claimed |
| EP-0708637-B1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM COMPRISING DENDRIMER POLYCATIONS | UNIV CALIFORNIA (US) | 2004-01-28 | — | — | EP | claimed |
| US-20040009602-A1 | DNA modifying molecules and methods of use thereof | THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2004-01-15 | — | — | US | claimed |
| US-20030198960-A1 | Signal amplifying targeted reporters for biological and chemical sensor applications | INTEGRATED NANOSYSTEMS, INC. | 2003-10-23 | — | — | US | claimed |
| US-6300317-B1 | EUKAROTIC CELLS, POLYNUCLEOTIDE, FUNCTIONAL AGENTS, MEMBRANE PERMEABILITY, SUBCELLAR LOCALIZATION AGENTS AND POLYNUCLEOTIDE MASKING AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-10-09 | — | — | US | claimed |
| US-6113946-A | EUKARYOTIC CELL, POLYNUCLEOTIDE AND DENDRIMER POLYCATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-09-05 | — | — | US | claimed |
| WO-2000028087-A1 | A LIBRARY OF MODIFIED PRIMERS FOR NUCLEIC ACID SEQUENCING, AND METHOD OF USE THEREOF | SEQUETECH CORPORATION (US) | 2000-05-18 | — | — | WO | claimed |
| US-5977084-A | INSERTION INTO CELLS; GENE THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-11-02 | — | — | US | claimed |
| US-5955365-A | INTRODUCING POLYNUCLEOTIDES INTO CELLS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-21 | — | — | US | claimed |
| EP-0636028-A4 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM. | UNIV CALIFORNIA (US) | 1998-12-09 | — | — | EP | claimed |
| EP-0708637-A4 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM COMPRISING DENDRIMER POLYCATIONS | UNIV CALIFORNIA (US) | 1998-08-12 | — | — | EP | claimed |
| EP-0774902-A1 | ANTISENSE AND TRIPLEX THERAPEUTIC AGENTS AND METHODS | Altman, Sidney (US) | 1997-05-28 | — | — | EP | claimed |
| EP-0708637-A1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM COMPRISING DENDRIMER POLYCATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-05-01 | — | — | EP | claimed |
| WO-1996004788-A1 | ANTISENSE AND TRIPLEX THERAPEUTIC AGENTS AND METHODS | ALTMAN SIDNEY (US) | 1996-02-22 | — | — | WO | claimed |
| EP-0636028-A1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-02-01 | — | — | EP | claimed |
| WO-1995002397-A1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM COMPRISING DENDRIMER POLYCATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-01-26 | — | — | WO | claimed |
| WO-1993019768-A1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-10-14 | — | — | WO | claimed |
| WO-1991002735-A1 | CHEMICAL COMPOUNDS BASED ON A NETROPSIN OR DISTAMYCIN MOLECULE COUPLED WITH AN INTERCALATING AGENT, METHOD FOR PREPARING SAID COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1991-03-07 | — | — | WO | claimed |
| US-20150297697-A1 | CANCER-ASSOCIATED ANTIGEN RELATED APPLICATIONS | VIVENTIA BIOTECHNOLOGIES INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-8946390-B2 | Cancer-associated antigen | VIVENTIA BIO INC. (CA) | 2015-02-03 | — | — | US | disclosed |
| US-20130243799-A1 | NOVEL CANCER-ASSOCIATED ANTIGEN | VIVENTIA BIOTECHNOLOGIES INC. (CA) | 2013-09-19 | — | — | US | disclosed |
| US-8389286-B2 | Cancer-associated antigen | VIVENTIA BIOTECHNOLOGIES INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120328602-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH CERAMIDE BIOSYNTHESIS | SAINT LOUIS UNIVERSITY (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120190568-A1 | GENETIC MARKERS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION, METHODS OF DETECTION AND USES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-07-26 | — | — | US | disclosed |
| EP-1976987-B1 | Cancer-associated Scratch variant | VIVENTIA BIOTECHNOLOGIES INC (CA) | 2012-06-27 | — | — | EP | disclosed |
| US-8153369-B2 | Assessment of risk for colorectal cancer | CANCER CARE ONTARIO (CA) | 2012-04-10 | — | — | US | disclosed |
| US-20120058106-A1 | NOVEL CANCER-ASSOCIATED ANTIGEN | VIVENTIA BIOTECHNOLOGIES INC. (CA) | 2012-03-08 | — | — | US | disclosed |
| US-8114592-B2 | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-02-14 | — | — | US | disclosed |
| US-20110189663-A1 | ASSESSMENT OF RISK FOR COLORECTAL CANCER | CANCER CARE ONTARIO (CA) | 2011-08-04 | — | — | US | disclosed |
| US-7977321-B2 | Small interfering RNAs targeting feline herpes virus | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2011-07-12 | — | — | US | disclosed |
| US-7956162-B2 | Cancer-associated antigen | VIVENTIA BIOTECHNOLOGIES INC. (CA) | 2011-06-07 | — | — | US | disclosed |
| EP-2243834-A1 | Assessment of risk for colorectal cancer | Cancer Care Ontario (CA) | 2010-10-27 | — | — | EP | disclosed |
| EP-2236623-A1 | Assessment of risk for colorectal cancer | Cancer Care Ontario (CA) | 2010-10-06 | — | — | EP | disclosed |
| US-20100086543-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH CERAMIDE BIOSYNTHESIS | SAINT LOUIS UNIVERSITY (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100047782-A1 | ASSESSMENT OF RISK FOR COLORECTAL CANCER | CANCER CARE ONTARIO (CA) | 2010-02-25 | — | — | US | disclosed |
| US-20100048680-A1 | Alpha-1-Antitrypsin Variants and Uses Thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20090305972-A1 | NOVEL CANCER-ASSOCIATED ANTIGEN | VIVENTIA BIO INC. (CA) | 2009-12-10 | — | — | US | disclosed |
| EP-2123306-A1 | Use of a decoy protein that interferes with the hedgehog signalling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization | Fondazione Telethon (IT) | 2009-11-25 | — | — | EP | disclosed |
| US-20090269761-A1 | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090203138-A1 | Small Interfering RNAs Targeting Feline Herpes Virus | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090192115-A1 | USE OF COMPOUNDS THAT INTERFERE WITH THE HEDGEHOG SIGNALING PATHWAY FOR THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING, INHIBITING, AND/OR REVERSING OCULAR DISEASES RELATED WITH OCULAR NEOVASCULARIZATION | FONDAZIONE TELETHON | 2009-07-30 | — | — | US | disclosed |
| EP-2079839-A1 | ASSESSMENT OF RISK FOR COLORECTAL CANCER | Cancer Care Ontario (CA) | 2009-07-22 | — | — | EP | disclosed |
| EP-1976987-A4 | NOVEL CANCER-ASSOCIATED ANTIGEN | VIVENTIA BIOTECH INC (CA) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009050507-A1 | COLORECTAL CANCER MARKERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2009-04-23 | — | — | WO | disclosed |
| US-7517870-B2 | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization | FONDAZIONE TELETHON (IT) | 2009-04-14 | — | — | US | disclosed |
| EP-2035439-A1 | ASSESSMENT OF RISK FOR COLORECTAL CANCER | Cancer Care Ontario (CA) | 2009-03-18 | — | — | EP | disclosed |
| EP-1976987-A1 | NOVEL CANCER-ASSOCIATED ANTIGEN | Viventia Biotech Inc. (CA) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008106785-A1 | ASSESSMENT OF RISK FOR COLORECTAL CANCER | CANCER CARE ONTARIO (CA) | 2008-09-12 | — | — | WO | disclosed |
| US-20080206252-A1 | Novel Polypeptides, and Nucleic Acids Encoding the Same | GENENTECH, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080166724-A1 | VEGF-Modulated Genes and Methods Employing Them | CURAGEN CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1265914-B1 | WNT-1 RELATED POLYPEPTIDES, AND NUCLEIC ACIDS ENCODING THE SAME | CURAGEN CORP (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007140599-A1 | ASSESSMENT OF RISK FOR COLORECTAL CANCER | CANCER CARE ONTARIO (CA) | 2007-12-13 | — | — | WO | disclosed |
| EP-1858497-A2 | USE OF COMPOUNDS THAT INTERFERE WITH THE HEDGEHOG SIGNALING PATHWAY FOR THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING, INHIBITING, AND/OR REVERSING OCULAR DISEASES RELATED WITH OCULAR NEOVASCULARIZATION | Fondazione Telethon (IT) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007071051-A1 | NOVEL CANCER-ASSOCIATED ANTIGEN | VIVENTIA BIOTECH INC. (CA) | 2007-06-28 | — | — | WO | disclosed |
| US-20070122885-A1 | METHODS OF INCREASING PRODUCTION OF SECONDARY METABOLITES BY MANIPULATING METABOLIC PATHWAYS THAT INCLUDE METHYLMALONYL-COA | FERMALOGIC, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-7223833-B1 | Peptide nucleic acid conjugates | ISIS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7202056-B2 | Polynucleotides encoding a human cell surface protein with immunoglobulin folds, BGS-19 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070071743-A1 | Novel human cell surface protein with immunoglobulin folds, BGS-19 | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-29 | — | — | US | disclosed |
| EP-1757618-A2 | ANGIOGENESIS-ASSOCIATED PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME | Curagen Corporation (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1578343-A4 | COMPOSITIONS AND METHODS FOR ADIPOSE ABUNDANT PROTEIN | GENENTECH INC (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1265920-B9 | ANGIOGENESIS-ASSOCIATED PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME | CURAGEN CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20070015700-A1 | Mammalian genes modulated during fasting and feeding | GENENTECH, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060294612-A1 | GPCR-LIKE RETINOIC ACID-INDUCED GENE 1 PROTEIN AND NUCLEIC ACID | CURAGEN CORPORATION (US) | 2006-12-28 | — | — | US | disclosed |
| US-7153685-B2 | Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060276391-A1 | Administering soluble Hedgehog interacting protein 1 (Hip1), obtained from Hip1 by deletion of the transmembrane segment located at the C-terminus, and optionally containing a signal peptide for therapy of age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma | FONDAZIONE TELETHON (IT) | 2006-12-07 | — | — | US | disclosed |
| EP-1265920-B1 | ANGIOGENESIS-ASSOCIATED PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME | CURAGEN CORP (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1501529-A4 | MAMMALIAN GENES MODULATED DURING FASTING AND FEEDING | GENENTECH INC (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006059357-A9 | USE OF COMPOUNDS THAT INTERFERE WITH THE HEDGEHOG SIGNALING PATHWAY FOR THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING, INHIBITING, AND/ OR REVERSING OCULAR DISEASES RELATED WITH OCULAR NEOVASCULARIZATION | FOND TELETHON (IT) | 2006-08-17 | — | — | WO | disclosed |
| EP-1562969-A4 | NOVEL HUMAN CELL SURFACE PROTEIN WITH IMMUNOGLOBULIN FOLDS, BGS-19 | BRISTOL MYERS SQUIBB CO (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1488233-A4 | NOVEL ACIDIC MAMMALIAN PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME | GENENTECH INC (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1493028-A4 | PHAGE DISPLAYED PDZ DOMAIN LIGANDS | GENENTECH INC (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006059357-A2 | USE OF COMPOUNDS THAT INTERFERE WITH THE HEDGEHOG SIGNALING PATHWAY FOR THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING, INHIBITING, AND/ OR REVERSING OCULAR DISEASES RELATED WITH OCULAR NEOVASCULARIZATION | FONDAZIONE TELETHON (IT) | 2006-06-08 | — | — | WO | disclosed |
| US-20060074023-A1 | Angiogenesis associated proteins, and nucleic acids encoding the same | CURAGEN CORPORATION (US) | 2006-04-06 | — | — | US | disclosed |
| EP-1309349-B1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF RETROVIRAL INFECTIONS | STICHTING REGA V Z W (BE) | 2005-11-09 | — | — | EP | disclosed |
| EP-1578343-A2 | COMPOSITIONS AND METHODS FOR ADIPOSE ABUNDANT PROTEIN | Genentech, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1294877-B1 | CGI-69 COMPOSITIONS AND METHODS OF USE | GENENTECH INC (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1562969-A2 | NOVEL HUMAN CELL SURFACE PROTEIN WITH IMMUNOGLOBULIN FOLDS, BGS-19 | Bristol-Myers Squibb Company (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1463523-A4 | GPCR-LIKE RETINOIC ACID-INDUCED GENE 1 PROTEIN AND NUCLEIC ACID | GENENTECH INC (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050159373-A1 | Novel polypeptides, and nucleic acids encoding the same | CURAGEN CORPORATION (US) | 2005-07-21 | — | — | US | disclosed |
| EP-1223173-B1 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS INC (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1290005-A4 | VEGF-MODULATED GENES AND METHODS EMPLOYING THEM | CURAGEN CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6872704-B2 | Acidic mammalian proteins and polynucleotides encoding the same | GENENTECH, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1282696-A4 | IFI206, A NOVEL INTERFERON-INDUCED POLYPEPTIDE, AND NUCLEIC ACIDS ENCODING THE SAME | CURAGEN CORP (US) | 2005-02-09 | — | — | EP | disclosed |
| EP-1501529-A1 | MAMMALIAN GENES MODULATED DURING FASTING AND FEEDING | Genentech Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1493028-A2 | PHAGE DISPLAYED PDZ DOMAIN LIGANDS | Genentech, Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| EP-1488233-A2 | NOVEL ACIDIC MAMMALIAN PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME | Genentech, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1463523-A2 | GPCR-LIKE RETINOIC ACID-INDUCED GENE 1 PROTEIN AND NUCLEIC ACID | GENENTECH, INC. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040171030-A1 | Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| EP-1383380-A4 | FIZZ1 FOR METABOLISM REGULATION | GENENTECH INC (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2004042029-A2 | OLIGOMERS COMPRISING MODIFIED BASES FOR BINDING CYTOSINE AND URACIL OR THYMINE AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2003004604-A9 | PHAGE DISPLAYED PDZ DOMAIN LIGANDS | GENENTECH INC (US) | 2004-04-15 | — | — | WO | disclosed |
| EP-0636028-B1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM COMPRISING AN AMPHIPHATIC CATIONIC PEPTIDE | UNIV CALIFORNIA (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20040025195-A1 | Novel human cell surface protein with immunoglobulin folds, BGS-19 | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-05 | — | — | US | disclosed |
| US-RE38416-E1 | NUCLEOTIDE BASES COMPRISING PYRAZOLO(3,4-D)PYRIMIDINES USED FOR MEDICAL DIAGNOSIS, THERAPY, HYBRIDIZATION, ANTISENSE AGENTS OR REPORTER MOLECULES | EPOCH BIOSCIENCES, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1383380-A2 | FIZZ1 FOR METABOLISM REGULATION | GENENTECH, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-0708637-B1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM COMPRISING DENDRIMER POLYCATIONS | UNIV CALIFORNIA (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20040009602-A1 | DNA modifying molecules and methods of use thereof | THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2004-01-15 | — | — | US | disclosed |
| US-20040006780-A1 | VEGF-modulated genes and methods employing them | GERBER HANS-PETER (US) | 2004-01-08 | — | — | US | disclosed |
| EP-0651759-B1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS INC (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003094949-A1 | MAMMALIAN GENES MODULATED DURING FASTING AND FEEDING | GENENTECH INC, ET AL. (US) | 2003-11-20 | — | — | WO | disclosed |
| US-20030207288-A1 | GPCR-like retinoic acid-induced gene 1 protein and nucleic acid | GENENTECH, INC. | 2003-11-06 | — | — | US | disclosed |
| US-20030208057-A1 | Mammalian genes modulated during fasting and feeding | GENENTECH, INC. | 2003-11-06 | — | — | US | disclosed |
| US-20030203375-A1 | Novel acidic mammalian proteins and polynucleotides encoding the same | GENENTECH, INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030198960-A1 | Signal amplifying targeted reporters for biological and chemical sensor applications | INTEGRATED NANOSYSTEMS, INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030199022-A1 | Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells | BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS | 2003-10-23 | — | — | US | disclosed |
| WO-2003083078-A2 | NOVEL HUMAN CELL SURFACE PROTEIN WITH IMMUNOGLOBULIN FOLDS, BGS-19 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030187003-A1 | Pharmaceutical compositions and method for the treatment of retroviral infections | STICHTING REGA VZW (BE) | 2003-10-02 | — | — | US | disclosed |
| US-6610663-B2 | Antisense compound with targeting and RNA cleaving moieties, preferably an imidazole functionality conjugated to the targeting oligonucleotide via linkers | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1334126-A1 | HUMAN STRA6-LIKE PROTEIN AND NUCLEIC ACIDS ENCODING THE SAME | Curagen Corporation (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20030148264-A1 | Phage displayed PDZ domain ligands | GENENTECH, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030104351-A1 | FIZZ1 for metabolism regulation | GENENTECH, INC. | 2003-06-05 | — | — | US | disclosed |
| EP-1309349-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF RETROVIRAL INFECTIONS | Stichting REGA V.Z.W. (BE) | 2003-05-14 | — | — | EP | disclosed |
| US-20030073613-A1 | Angiogenisis associated proteins, and nucleic acids encoding the same | GENENTECH, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003031582-A2 | NOVEL ACIDIC MAMMALIAN PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME | GENENTECH, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-1294877-A2 | CGI-69 COMPOSITIONS AND METHODS OF USE | Genentech, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1290009-A1 | PLANT PROMOTER | Colorado State University (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1290005-A2 | VEGF-MODULATED GENES AND METHODS EMPLOYING THEM | Curagen Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2003016553-A2 | GPCR-LIKE RETINOIC ACID-INDUCED GENE 1 PROTEIN AND NUCLEIC ACID | GENENTECH, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1282696-A1 | IFI206, A NOVEL INTERFERON-INDUCED POLYPEPTIDE, AND NUCLEIC ACIDS ENCODING THE SAME | Curagen Corporation (US) | 2003-02-12 | — | — | EP | disclosed |
| US-20030021788-A1 | Novel human STRA6-like protein and nucleic acids encoding the same | GENENTECH, INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2003004604-A2 | PHAGE DISPLAYED PDZ DOMAIN LIGANDS | GENENTECH, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
| EP-1265914-A2 | WNT-1 RELATED POLYPEPTIDES, AND NUCLEIC ACIDS ENCODING THE SAME | Curagen Corporation (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1265920-A2 | ANGIOGENESIS-ASSOCIATED PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME | Curagen Corporation (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2002097036-A2 | COMPOSITIONS AND METHODS FOR ADIPOSE ABUNDANT PROTEIN | GENENTECH, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002096355-A2 | COMPOSITIONS AND METHODS FOR ADIPOSE ABUNDANT PROTEIN | GENENTECH, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020160972-A1 | Compositions and methods for modulating RNA | ISIS PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | disclosed |
| WO-2002079383-A2 | FIZZ1 FOR METABOLISM REGULATION | GENENTECH, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002077027-A1 | HUMAN STRA6-LIKE PROTEIN AND NUCLEIC ACIDS ENCODING THE SAME | CURAGEN CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020132978-A1 | VEGF-modulated genes and methods employing them | CURAGEN CORPORATION | 2002-09-19 | — | — | US | disclosed |
| EP-1236473-A2 | Self-assembling polynucleotide delivery system | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20020119137-A1 | CGI-69 compositions and methods of use | GENENTECH, INC. | 2002-08-29 | — | — | US | disclosed |
| EP-0804456-B1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1223173-A2 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS, INC. (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2002051419-A2 | A PHARMACEUTICAL COMPOSITION CONTAINING BENZOPYRANO-OXOPYRIMIDOTETRAHYDROTHIAZINE AND ITS USE IN THE TREATMENT OF HIV | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2002-07-04 | — | — | WO | disclosed |
| US-20020068290-A1 | Topoisomerase activated oligonucleotide adaptors and uses therefor | UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE | 2002-06-06 | — | — | US | disclosed |
| US-6358931-B1 | OLIGONUCLETIDE CONJUGATED TO IMIDAZOLE; INTERCALATION AND COORDINATION COMPOUNDS; MEDICAL DIAGNOSIS, GENE THERAPY; ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
| WO-2002003971-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF RETROVIRAL INFECTIONS | STICHTING REGA VZW (BE) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001098355-A2 | CGI-69 COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| US-6320040-B1 | PREPARING NOVEL NUCLEOSIDE OLIGOMERS BEARING PENDANT CONJUGATE GROUPS FOR INCORPORATION INTO NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. | 2001-11-20 | — | — | US | disclosed |
| WO-2001085754-A1 | PLANT PROMOTER | COLORADO STATE UNIVERSITY THROUGH ITS AGENT COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001079467-A2 | IDENTIFICATION OF A RENAL NADPH OXIDASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY OF THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2001-10-25 | — | — | WO | disclosed |
| US-6300317-B1 | EUKAROTIC CELLS, POLYNUCLEOTIDE, FUNCTIONAL AGENTS, MEMBRANE PERMEABILITY, SUBCELLAR LOCALIZATION AGENTS AND POLYNUCLEOTIDE MASKING AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-10-09 | — | — | US | disclosed |
| WO-2001070174-A2 | VEGF-MODULATED GENES AND METHODS EMPLOYING THEM | CURAGEN CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001070808-A2 | ANGIOGENESIS - ASSOCIATED PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME | CURAGEN CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001070775-A2 | WNT-1 RELATED POLYPEPTIDES, AND NUCLEIC ACIDS ENCODING THE SAME | CURAGEN CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001068830-A1 | IFI206, A NOVEL INTERFERON-INDUCED POLYPEPTIDE, AND NUCLEIC ACIDS ENCODING THE SAME | CURAGEN CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
| US-6242592-B1 | Process for the preparation of 2′-O-alkyl-guanosine, cytidine, and uridine phosphoramidites | ISIS PHARMACEUTICALS, INC. | 2001-06-05 | — | — | US | disclosed |
| US-6133438-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6113946-A | EUKARYOTIC CELL, POLYNUCLEOTIDE AND DENDRIMER POLYCATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-09-05 | — | — | US | disclosed |
| US-6087482-A | INTER-SUGAR LINKAGES ARE FOUR ATOM LINKING GROUPS; FOR IMPROVED NUCLEASE RESISTANCE AND CELLULAR UPTAKE; FOR DIAGNOSIS AND ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| WO-2000028087-A1 | A LIBRARY OF MODIFIED PRIMERS FOR NUCLEIC ACID SEQUENCING, AND METHOD OF USE THEREOF | SEQUETECH CORPORATION (US) | 2000-05-18 | — | — | WO | disclosed |
| US-5998603-A | TETRAHYDROFURANYL COMPOUNDS ARE PROVIDED THAT ARE FUNCTIONALIZED TO INCLUDE PENDANT CONJUGATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5990089-A | INTRODUCING A POLYNUCLEOTIDE INTO A EUKARYOTIC CELL IN A LIVING ANIMAL COMPRISING CONTACTING THE CELL WITH A COMPOSITION COMPRISING A POLYNUCLEOTIDE AND A DENDRIMER POLYCATION COUPLED TO THE POLYNUCLEOTIDE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-11-23 | — | — | US | disclosed |
| US-5977084-A | INSERTION INTO CELLS; GENE THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-11-02 | — | — | US | disclosed |
| US-5955365-A | INTRODUCING POLYNUCLEOTIDES INTO CELLS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-21 | — | — | US | disclosed |
| US-5914396-A | 2'-O-modified nucleosides and phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-06-22 | — | — | US | disclosed |
| EP-0804456-A4 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5856466-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0636028-A4 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM. | UNIV CALIFORNIA (US) | 1998-12-09 | — | — | EP | disclosed |
| US-5824796-A | MEDICAL DIAGNOSIS WITH TARGET DNA OR RNA FOR ENZYME INHIBITORS | EPOCH PHARMACEUTICALS, INC. (US) | 1998-10-20 | — | — | US | disclosed |
| EP-0708637-A4 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM COMPRISING DENDRIMER POLYCATIONS | UNIV CALIFORNIA (US) | 1998-08-12 | — | — | EP | disclosed |
| EP-0543913-B1 | OLIGO(ALPHA-ARABINOFURANOSYL NUCLEOTIDES) AND ALPHA-ARABINOFURANOSYL PRECURSORS THEREOF | EPOCH PHARMACEUTICALS INC (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5688941-A | Methods of making conjugated 4' desmethyl nucleoside analog compounds | ISIS PHARMACEUTICALS, INC. (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0804456-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5677437-A | MACROMOLECULES; REGULATING RNA EXPRESSION; THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 1997-10-14 | — | — | US | disclosed |
| US-5661025-A | TRANSFERRING A POLYNUCLOTIDE INTO EUKARYOTIC CELL IN VITRO COMPRISES A DENDRIMER POLYCATION AIDING IN THE DELIVERY OF POLYNUCLEOTIDE TO DESIRED ADDRESS | UNIV CALIFORNIA (US) | 1997-08-26 | — | — | US | disclosed |
| US-5646265-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMCEUTICALS, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0774902-A1 | ANTISENSE AND TRIPLEX THERAPEUTIC AGENTS AND METHODS | Altman, Sidney (US) | 1997-05-28 | — | — | EP | disclosed |
| EP-0656747-A4 | COMPOSITION AND METHOD FOR ALTERING DNA SEQUENCES BY HOMOLOGOUS RECOMBINATION. | UNIV CALIFORNIA (US) | 1997-05-07 | — | — | EP | disclosed |
| US-5608046-A | Conjugated 4'-desmethyl nucleoside analog compounds | ISIS PHARMACEUTICALS, INC. (US) | 1997-03-04 | — | — | US | disclosed |
| WO-1996011205-A9 | PEPTIDE NUCLEIC ACID CONJUGATES | — | 1996-05-30 | — | — | WO | disclosed |
| US-5514786-A | Compositions for inhibiting RNA activity | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0708637-A1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM COMPRISING DENDRIMER POLYCATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1996011205-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996010030-A1 | OLIGOMERS HAVING HETEROATOM-LINKED CONJUGATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| WO-1996004788-A1 | ANTISENSE AND TRIPLEX THERAPEUTIC AGENTS AND METHODS | ALTMAN SIDNEY (US) | 1996-02-22 | — | — | WO | disclosed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0543913-A4 | OLIGO(ALPHA-ARABINOFURANOSYL NUCLEOTIDES) AND ALPHA-ARABINOFURANOSYL PRECURSORS THEREOF | MICROPROBE CORP (US) | 1995-10-04 | — | — | EP | disclosed |
| US-5441941-A | 1,2-dihydroellipticines with activity against CNS specific cancer | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF DHHS (US) | 1995-08-15 | — | — | US | disclosed |
| EP-0656790-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-14 | — | — | EP | disclosed |
| EP-0656747-A1 | COMPOSITION AND METHOD FOR ALTERING DNA SEQUENCES BY HOMOLOGOUS RECOMBINATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-06-14 | — | — | EP | disclosed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0636028-A1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-02-01 | — | — | EP | disclosed |
| WO-1995002397-A1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM COMPRISING DENDRIMER POLYCATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-01-26 | — | — | WO | disclosed |
| US-5359051-A | Compounds useful in the synthesis of nucleic acids capable of cleaning RNA | ISIS PHARMACEUTICALS (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994022886-A1 | HETEROATOMIC OLIGONUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994004032-A1 | COMPOSITION AND METHOD FOR ALTERING DNA SEQUENCES BY HOMOLOGOUS RECOMBINATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-03-03 | — | — | WO | disclosed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
| US-5272146-A | 1,2-dihydroellipticines with activity against CNS specific cancer cell lines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-12-21 | — | — | US | disclosed |
| WO-1993023570-A1 | OLIGONUCLEOTIDES HAVING CONJUGATES ATTACHED AT THE 2'-POSITION OF THE SUGAR MOIETY | PHARMAGENICS, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993019768-A1 | SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-10-14 | — | — | WO | disclosed |
| WO-1993017717-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
| EP-0543913-A1 | OLIGO(ALPHA-ARABINOFURANOSYL NUCLEOTIDES) AND ALPHA-ARABINOFURANOSYL PRECURSORS THEREOF | EPOCH PHARMACEUTICALS, INC. (US) | 1993-06-02 | — | — | EP | disclosed |
| EP-0290583-B1 | $g(a) OLIGONUCLEOTIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1993-04-07 | — | — | EP | disclosed |
| WO-1993003736-A1 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION | MICROPROBE CORPORATION (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5177196-A | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof | MICROPROBE CORPORATION (US) | 1993-01-05 | — | — | US | disclosed |
| WO-1992003577-A1 | OLIGO(ALPHA-ARABINOFURANOSYL NUCLEOTIDES) AND ALPHA-ARABINOFURANOSYL PRECURSORS THEREOF | MICROPROBE CORPORATION (US) | 1992-03-05 | — | — | WO | disclosed |
| WO-1991002735-A1 | CHEMICAL COMPOUNDS BASED ON A NETROPSIN OR DISTAMYCIN MOLECULE COUPLED WITH AN INTERCALATING AGENT, METHOD FOR PREPARING SAID COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1991-03-07 | — | — | WO | disclosed |
| WO-1990003370-A1 | DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE | MICROPROBE CORPORATION (US) | 1990-04-05 | — | — | WO | disclosed |
| EP-0290583-A1 | -g(a) OLIGONUCLEOTIDES. | CENTRE NAT RECH SCIENT (FR) | 1988-11-17 | — | — | EP | disclosed |
| WO-1988004301-A1 | alpha OLIGONUCLEOTIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 1988-06-16 | — | — | WO | disclosed |
| WO-1988004301-A1 | alpha OLIGONUCLEOTIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 1988-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187003-A1 | Pharmaceutical compositions and method for the treatment of retroviral infections | TYMP, DPYD, TPMT | KIF11 4680/4885TDO2 1758/4885HTR2B 4532/4885 |
| US-20030021788-A1 | Novel human STRA6-like protein and nucleic acids encoding the same | DDX21, PABPC4, MYL6 | KIF11 2558/4885TDO2 3607/4885HTR2B 4528/4885 |
| US-20090192115-A1 | USE OF COMPOUNDS THAT INTERFERE WITH THE HEDGEHOG SIGNALING PATHWAY FOR THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING, INHIBITING, AND/OR REVERSING OCULAR DISEASES RELATED WITH OCULAR NEOVASCULARIZATION | SHH, GLI1, SMO | KIF11 3256/4885TDO2 4088/4885HTR2B 4098/4885 |
| US-20020160972-A1 | Compositions and methods for modulating RNA | RNGTT, NSUN3, NSUN2 | KIF11 2231/4885TDO2 4054/4885HTR2B 3113/4885 |
| US-20060294612-A1 | GPCR-LIKE RETINOIC ACID-INDUCED GENE 1 PROTEIN AND NUCLEIC ACID | RARG, RXRG, GPR65 | KIF11 1738/4885TDO2 4398/4885HTR2B 2869/4885 |
| US-20030148264-A1 | Phage displayed PDZ domain ligands | PDLIM5, CD2BP2, GOPC | KIF11 1956/4885TDO2 4370/4885HTR2B 4343/4885 |
| US-20020132978-A1 | VEGF-modulated genes and methods employing them | FLT4, VEGFA, FLT1 | KIF11 3437/4885TDO2 4616/4885HTR2B 4354/4885 |
| US-20040171030-A1 | Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation | RNMT, NSUN2, DCLRE1B | KIF11 3615/4885TDO2 3773/4885HTR2B 3888/4885 |
| US-20050159373-A1 | Novel polypeptides, and nucleic acids encoding the same | DDX21, PABPC4, UPF1 | KIF11 2103/4885TDO2 4378/4885HTR2B 4734/4885 |
| US-20080206252-A1 | Novel Polypeptides, and Nucleic Acids Encoding the Same | DDX21, PABPC4, UPF1 | KIF11 2103/4885TDO2 4378/4885HTR2B 4734/4885 |
| US-20060276391-A1 | Administering soluble Hedgehog interacting protein 1 (Hip1), obtained from Hip1 by deletion of the transmembrane segment located at the C-terminus, and optionally containing a signal peptide for therapy of age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma | SHH, HIPK1, HIPK3 | KIF11 3829/4885TDO2 4685/4885HTR2B 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.